Account-creators
1,040
edits
Difference between revisions of "Subependymal giant cell astrocytoma"
Jump to navigation
Jump to search
Subependymal giant cell astrocytoma (view source)
Revision as of 08:37, 14 October 2019
, 08:37, 14 October 2019→General: Update
Jensflorian (talk | contribs) (infobox) |
Jensflorian (talk | contribs) (→General: Update) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 36: | Line 36: | ||
*Associated with [[tuberous sclerosis complex]] (TSC).<ref name=pmid21455842>{{Cite journal | last1 = Grajkowska | first1 = W. | last2 = Kotulska | first2 = K. | last3 = Jurkiewicz | first3 = E. | last4 = Roszkowski | first4 = M. | last5 = Daszkiewicz | first5 = P. | last6 = Jóźwiak | first6 = S. | last7 = Matyja | first7 = E. | title = Subependymal giant cell astrocytomas with atypical histological features mimicking malignant gliomas. | journal = Folia Neuropathol | volume = 49 | issue = 1 | pages = 39-46 | month = | year = 2011 | doi = | PMID = 21455842 }}</ref> | *Associated with [[tuberous sclerosis complex]] (TSC).<ref name=pmid21455842>{{Cite journal | last1 = Grajkowska | first1 = W. | last2 = Kotulska | first2 = K. | last3 = Jurkiewicz | first3 = E. | last4 = Roszkowski | first4 = M. | last5 = Daszkiewicz | first5 = P. | last6 = Jóźwiak | first6 = S. | last7 = Matyja | first7 = E. | title = Subependymal giant cell astrocytomas with atypical histological features mimicking malignant gliomas. | journal = Folia Neuropathol | volume = 49 | issue = 1 | pages = 39-46 | month = | year = 2011 | doi = | PMID = 21455842 }}</ref> | ||
** 6-14% of all TSC patients will develop a SEGA. | ** 6-14% of all TSC patients will develop a SEGA. | ||
** Sporadic examples of SEGA may represent undetected TSC patients (i.e., low-level somatic mosaicism)<ref>{{Cite journal | last1 = Overwater | first1 = IE. | last2 = Swenker | first2 = R. | last3 = van der Ende | first3 = EL. | last4 = Hanemaayer | first4 = KB. | last5 = Hoogeveen-Westerveld | first5 = M. | last6 = van Eeghen | first6 = AM. | last7 = Lequin | first7 = MH. | last8 = van den Ouweland | first8 = AM. | last9 = Moll | first9 = HA. | title = Genotype and brain pathology phenotype in children with tuberous sclerosis complex. | journal = Eur J Hum Genet | volume = 24 | issue = 12 | pages = 1688-1695 | month = 12 | year = 2016 | doi = 10.1038/ejhg.2016.85 | PMID = 27406250 }}</ref>. | |||
*Associated with epilepsy. | *Associated with epilepsy. | ||
*WHO Grade I. | *WHO Grade I. | ||
| Line 80: | Line 81: | ||
*Synaptophysin +/-ve (ganglionic component).. | *Synaptophysin +/-ve (ganglionic component).. | ||
*[[TTF-1]] (7 out of 7).<ref name=pmid25669749>{{Cite journal | last1 = Hewer | first1 = E. | last2 = Vajtai | first2 = I. | title = Consistent nuclear expression of thyroid transcription factor 1 in subependymal giant cell astrocytomas suggests lineage-restricted histogenesis. | journal = Clin Neuropathol | volume = 34 | issue = 3 | pages = 128-31 | month = | year = | doi = 10.5414/NP300818 | PMID = 25669749 }}</ref> | *[[TTF-1]] (7 out of 7).<ref name=pmid25669749>{{Cite journal | last1 = Hewer | first1 = E. | last2 = Vajtai | first2 = I. | title = Consistent nuclear expression of thyroid transcription factor 1 in subependymal giant cell astrocytomas suggests lineage-restricted histogenesis. | journal = Clin Neuropathol | volume = 34 | issue = 3 | pages = 128-31 | month = | year = | doi = 10.5414/NP300818 | PMID = 25669749 }}</ref> | ||
*Olig2-ve.<ref>{{Cite journal | last1 = Overwater | first1 = IE. | last2 = Swenker | first2 = R. | last3 = van der Ende | first3 = EL. | last4 = Hanemaayer | first4 = KB. | last5 = Hoogeveen-Westerveld | first5 = M. | last6 = van Eeghen | first6 = AM. | last7 = Lequin | first7 = MH. | last8 = van den Ouweland | first8 = AM. | last9 = Moll | first9 = HA. | title = Genotype and brain pathology phenotype in children with tuberous sclerosis complex. | journal = Eur J Hum Genet | volume = 24 | issue = 12 | pages = 1688-1695 | month = 12 | year = 2016 | doi = 10.1038/ejhg.2016.85 | PMID = 27406250 }}</ref> | |||
* MIB-1 usu. low (1-5%). | * MIB-1 usu. low (1-5%). | ||